FIELD: medicine.
SUBSTANCE: group of inventions relate to field of pharmaceutics, in particular, to pharmaceutical composition for treatment of phenylketonuria, which contains effective quantity of version of Anabaena variabilis (AvPAL) phenylalanine-ammonia-lyase, where claimed version additionally contains polyethylenglycol, as well as pharmaceutically acceptable carrier, which contains stabiliser, where stabiliser represents L-phenylalanine, trans-cinnamic acid or benzoic acid. Also claimed are: method of phenylketonuria treatment and method of reducing phenylalanine concentration in subject's blood.
EFFECT: group of inventions ensure application of prokaryotic PAL, which has higher phenylalanine-converting activity and/or lower immunogenicity in comparison with PAL of wild type.
56 cl, 19 ex, 11 tbl, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STREPTOKINASE MUTANTS AND THEIR COVALENTLY MODIFIED FORMS | 2009 |
|
RU2542392C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER WITH ARGININE-DEPLETING AND IMMUNE-ONCOLOGICAL AGENTS | 2017 |
|
RU2771313C2 |
| MODIFIED ANTAGONIST OF RECEPTOR IL-4 AND PURIFIED POLYNUCLEOTIDE INTENDED FOR ITS PRODUCTION | 2004 |
|
RU2389796C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| NEW VERSION OF EXENDIN OR ITS CONJUGATE | 2010 |
|
RU2528734C2 |
| HGF BETA-CHAIN VERSIONS | 2006 |
|
RU2403261C2 |
| FUNCTIONALISED POLYPEPTIDES | 2009 |
|
RU2582244C2 |
| METHOD FOR IDENTIFYING SITES FOR IgG CONJUGATIONS | 2010 |
|
RU2569186C2 |
| ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUITIONS AND THEIR CONJUGATES PRODUCED BY GENE ENGINEERING | 2011 |
|
RU2626537C2 |
